



**PATENT**

Case Docket No. AVERA.13DVDV1DV

Date: October 1, 2003

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s) : Godfrey, et al.  
Appl. No. : 10/613,798  
Filed : 02-Jul-2003  
For : ARYLPEPERAZINES HAVING  
ACTIVITY AT THE  
SEROTONIN 1A RECEPTOR  
Examiner : Unassigned  
Group Art Unit : 1614

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

October 1, 2003

(Date)

Rose M. Thiessen, Reg. No. 40,202

**TRANSMITTAL LETTER**


Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

Rose M. Thiessen  
Registration No. 40,202  
Attorney of Record  
Customer No. 20,995  
(619) 235-8550



## INFORMATION DISCLOSURE STATEMENT

Applicant : Godfrey, et al.  
App. No. : 10/613,798  
Filed : April 16, 2003  
For : ARYLPEPERAZINES HAVING ACTIVITY  
AT THE SEROTONIN 1A RECEPTOR  
Examiner : Unassigned  
Group Art Unit : 1614

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing 27 references that were previously disclosed to or cited by the Patent and Trademark Office in the prosecution of earlier filed U.S. utility applications to which the present application claims priority. The present application is a division of Application No. 10/022,045, filed December 18, 2001, which is a division of Application No. 09/753,645 filed January 3, 2001, now Patent No. 6,358,958, which is a division of Application No. 09/208,553, filed December 9, 1998, now Patent No. 6,239,135. Copies of the references are not submitted pursuant to 37 C.F.R. § 1.98(d).

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: Oct 1, 2003

By: 

Rose M. Thiessen  
Registration No. 40,202  
Attorney of Record  
Customer No. 20,995  
(619) 235-8550

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
AVERA.13DVEDV1DVAPPLICATION NO.  
10/613,798INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
Godfrey, et al.FILING DATE  
July 2, 2003GROUP  
1614

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1	5,693,642	12/1997	Cliffe et al.			
	2	5,346,896	09/1994	Ward et al.			
	3	5,340,812	08/1994	Cliffe			
	4	4,988,814	01/1991	Abou-Gharbia et al.			
	5	5,614,523	03/1997	Audia et al.			
	6	5,541,326	07/1996	Cliffe			
	7	4,536,516	08/1985	Harper et al.			
	8	5,292,732	03/1994	Rover			

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	9	EP 0521368	01/1993	EP				
	10	EP 0661266 A1	07/1995	EP				
	11	EP 0512755	11/1992	EP				
	12	WO 94/21610	09/1994	WIPO				
	13	GB 2,303,303 A	02/1997	Great Britain				
	14	WO 92/06082	04/1992	WIPO				
	15	GB 2,248,499 A	04/1992	Great Britain				
	16	CN 1076446 A	09/1993	China				
	17	BE 637389		Belgium				

EXAMINER  
INITIAL

## OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

	18	ID Patent Fast Alert, 07/1997, citing GB 2303303A.
	19	Morren, H. et al., Industrie Chimique Belge, 28(2), 123 (1963).
	20	Rasmussen, K. and V. Rocco, Annual Reports Med. Chem., 30(1), 1 (1995).
	21	E. Diez-Barra et al., Tetrahedron, 53(33), 11437-11448 (1997).

EXAMINER

DATE CONSIDERED

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
AVERA.13DVDV1DVAPPLICATION NO.  
10/613,798INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
Godfrey, et al.FILING DATE  
July 2, 2003GROUP  
1614

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	22	E. C. Dodds et al., Proceedings of the Royal Society of London, Series B; Biological Sciences, 127, 140-167 (1939).
	23	T. Kawabata et al., Journal of the American Chemical Society, 113(25), 9694-9696 (1991).
	24	Chemical Abstracts, 115(26), December 30, 1991, Abstract No. 280741k.
	25	Heme, Hans-George, Justus Liebigs Annalen Der Chemie, 735, 56-64 (1970).
	26	Saxena, Pramod R., Pharmac. Ther., 66, 339-368 (1995).
	27	Robichaud et al., Annual Reports in Medicinal Chemistry, 11-20 (2000).

S:\DOCS\RM\T\RM\T-2021.DOC  
100103

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>	